Immunome Inc. Q1 2025 10-Q: Assets $87M, Liabilities $64M
Ticker: IMNM · Form: 10-Q · Filed: May 12, 2025 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, equity, agreements
TL;DR
**Immunome Q1 2025:** Assets $87M, Liabilities $64M. Equity movements detailed.
AI Summary
Immunome Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $86.96 million and total liabilities of $64.46 million. Key financial activities during the first quarter of 2025 included common stock transactions and other equity movements, with specific details on purchase agreements with Zentalis and Ayala.
Why It Matters
This filing provides a snapshot of Immunome's financial health and operational activities for the first quarter of 2025, including significant asset and liability figures and details on strategic agreements.
Risk Assessment
Risk Level: medium — The company's financial position shows a significant gap between assets and liabilities, and the filing details specific equity transactions which can indicate financial strategy and potential future dilution.
Key Numbers
- $86.96M — Total Assets (As of March 31, 2025)
- $64.46M — Total Liabilities (As of March 31, 2025)
Key Players & Entities
- Immunome Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- $86,955,855 (dollar_amount) — Total assets
- $64,460,829 (dollar_amount) — Total liabilities
- Zentalis (company) — Party to a purchase agreement
- Ayala (company) — Party to a purchase agreement
FAQ
What were the specific common stock transactions during Q1 2025?
The filing indicates common stock transactions occurred between January 1, 2025, and March 31, 2025, including open market sales and transactions related to purchase agreements with Zentalis and Ayala.
What is the nature of the purchase agreements mentioned with Zentalis and Ayala?
The filing references purchase agreements with Zentalis and Ayala, involving common stock and additional paid-in capital, during the periods of January 1, 2024, to March 31, 2024, and January 1, 2025, to March 31, 2025.
What was the retained earnings balance as of March 31, 2025?
The retained earnings balance as of March 31, 2025, is not explicitly stated as a single figure in the provided snippet, but the context indicates it is a component of the company's equity.
What is the company's fiscal year end?
Immunome Inc.'s fiscal year ends on December 31.
What is the company's primary business SIC code?
Immunome Inc.'s Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Immunome Inc. (IMNM).